These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities--long-term follow-up of a randomised trial. Olofsson Bagge R; Mattsson J; Hafström L Int J Hyperthermia; 2014 Aug; 30(5):295-8. PubMed ID: 25144818 [TBL] [Abstract][Full Text] [Related]
27. Hyperthermic antiblastic perfusion with TNFalpha and melphalan in stage III limb melanoma patients: A phase I - II SITILO study. Di Filippo F; Rossi CR; Garinei R; Anzà M; Cavaliere F; Botti C; Perri P; Di Filippo S; Di Angelo P; Principi F; Laurenzi L J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):97-101. PubMed ID: 16767914 [TBL] [Abstract][Full Text] [Related]
28. Melphalan monitoring during hyperthermic perfusion of isolated limb for melanoma: pharmacokinetic study and 99mTc-albumin microcolloid technique. Cattel L; Buffa E; De Simone M; Cesana P; Novello S; Dosio F; Ceruti M Anticancer Res; 2001; 21(3C):2243-8. PubMed ID: 11501854 [TBL] [Abstract][Full Text] [Related]
29. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan. Thom AK; Alexander HR; Andrich MP; Barker WC; Rosenberg SA; Fraker DL J Clin Oncol; 1995 Jan; 13(1):264-73. PubMed ID: 7799030 [TBL] [Abstract][Full Text] [Related]
34. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group. Hafström L; Rudenstam CM; Blomquist E; Ingvar C; Jönsson PE; Lagerlöf B; Lindholm C; Ringborg U; Westman G; Ostrup L J Clin Oncol; 1991 Dec; 9(12):2091-4. PubMed ID: 1960549 [TBL] [Abstract][Full Text] [Related]
35. Isolated limb perfusion for unresectable melanoma of the extremities. Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572 [TBL] [Abstract][Full Text] [Related]
36. Treatment of in-transit metastases from cutaneous melanoma by isolation perfusion with tumour necrosis factor-alpha (TNF-alpha), melphalan and interferon-gamma (IFN-gamma). Dose-finding experience at the National Cancer Institute of Milan. Vaglini M; Santinami M; Manzi R; Inglese MG; Santoro N; Persiani L; Belli F Melanoma Res; 1994 Mar; 4 Suppl 1():35-8. PubMed ID: 8038594 [TBL] [Abstract][Full Text] [Related]
37. TNF-alpha levels in patients with malignant tumors after hyperthermic isolated regional perfusion. Aksaz E; Erdem E; Erdem D; Unal AM J Exp Clin Cancer Res; 2002 Dec; 21(4):489-93. PubMed ID: 12636094 [TBL] [Abstract][Full Text] [Related]
38. Rapid increase in plasma tenascin-C concentration after isolated limb perfusion with high-dose tumor necrosis factor (TNF), interferon gamma (IFN gamma) and melphalan for regionally advanced tumors. Schienk S; Liénard D; Gerain J; Baumgartner M; Lejeune FJ; Chiquet-Ehrismann R; Rüegg C Int J Cancer; 1995 Nov; 63(5):665-72. PubMed ID: 7591283 [TBL] [Abstract][Full Text] [Related]